Early intervention in Spinal Muscular Atrophy is crucial for better outcomes, emphasizing the need for timely treatment to prevent irreversible disability.
Clinical Brief: Treatment Timing for Patients With SMA Across Age Groups
Main Discussion Topics
Key Points for Physicians
Notable Insights
Assessment tools developed for specific age groups or functional levels may have floor/ceiling effects that limit their utility in other populations, necessitating alternative evaluation methods to document meaningful changes.
Clinical Significance
While treatment timing is critical across all SMA age groups, physicians must adapt intervention timelines and outcome measurements to appropriately assess and document treatment benefits in older patients.
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD
May 21st 2025The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.
Read More
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
May 17th 2025The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Read More